Journal of Cardiovascular Pharmacology and Therapeutics

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Free Full Text (Free PDF) Free
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gorelick, P.
Right arrow Articles by Hennekens, C. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gorelick, P.
Right arrow Articles by Hennekens, C. H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Journal of Cardiovascular Pharmacology and Therapeutics, Vol. 11, No. 4, 245-248 (2006)
DOI: 10.1177/1074248406296862

Evolving Perspectives on Clopidogrel in the Treatment of Ischemic Stroke

Philip Gorelick, MD, MPH

Department of Neurology and Center for Stroke Research, University of Illinois College of Medicine at Chicago, pgorelic{at}uic.edu

Oksana Sechenova, RPh

Bethesda Hospital, Boynton Beach, Florida

Charles H. Hennekens, MD, DrPH

Department of Biomedical Science, Center of Excellence, Florida Atlantic University, Boca Raton, Department of Medicine and Department of Epidemiology and Public Health, University of Miami Miller School of Medicine, Miami, Florida

Antiplatelet therapy is indicated for the treatment of ischemic stroke or transient ischemic attack (TIA). Aspirin reduces subsequent occlusive vascular events, including recurrent stroke, by about 25%. In such patients, clopidogrel has been evaluated in an effort to further reduce risk. In the Management of Atherothrombosis with Clopidogrel in High-risk Patients trial, the combination of clopidogrel plus aspirin was compared with clopidogrel alone, and the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance trial tested the addition of clopidogrel to aspirin. Combination therapy with aspirin plus clopidogrel provided no significant incremental benefit compared with aspirin or clopidogrel alone. In addition, combination therapy increased the risk of serious bleeding. On the basis of the current totality of evidence for long-term treatment of survivors of ischemic stroke or TIA, clopidogrel is an effective alternative for patients who are intolerant to aspirin.

Key Words: antiplatelet therapy • aspirin • CHARISMA • clopidogrel • ischemic stroke • MATCH


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?